Search: onr:"swepub:oai:DiVA.org:his-16305" >
Utilizing microphys...
Utilizing microphysiological systems and induced pluripotent stem cells for disease modeling : a case study for blood brain barrier research in a pharmaceutical setting
-
- Fabre, Kristin M. (author)
- Microphysiological Systems Center of Excellence, Drug Safety & Metabolism, IMED Biotech Unit, AstraZeneca, Waltham, MA, United States
-
- Delsing, Louise (author)
- Gothenburg University,Göteborgs universitet,Högskolan i Skövde,Institutionen för biovetenskap,Forskningscentrum för Systembiologi,Discovery Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden / Institute of Neuroscience and Physiology, Department of Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden,Bioinformatik, Bioinformatics,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
-
- Hicks, Ryan (author)
- Discovery Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden
-
show more...
-
- Colclough, Nicola (author)
- Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom
-
- Crowther, Damian C. (author)
- Neuroscience, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom
-
- Ewart, Lorna (author)
- Microphysiological Systems Center of Excellence, Drug Safety & Metabolism, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom
-
show less...
-
(creator_code:org_t)
- Elsevier, 2019
- 2019
- English.
-
In: Advanced Drug Delivery Reviews. - : Elsevier. - 0169-409X .- 1872-8294. ; 140, s. 129-135
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
https://gup.ub.gu.se...
-
show less...
Abstract
Subject headings
Close
- Microphysiological systems (MPS) may be able to provide the pharmaceutical industry models that can reflect human physiological responses to improve drug discovery and translational outcomes. With lack of efficacy being the primary cause for drug attrition, developing MPS disease models would help researchers identify novel targets, study mechanisms in more physiologically-relevant depth, screen for novel biomarkers and test/optimize various therapeutics (small molecules, nanoparticles and biologics). Furthermore, with advances in inducible pluripotent stem cell technology (iPSC), pharmaceutical companies can access cells from patients to help recreate specific disease phenotypes in MPS platforms. Combining iPSC and MPS technologies will contribute to our understanding of the complexities of neurodegenerative diseases and of the blood brain barrier (BBB) leading to development of enhanced therapeutics. © 2018
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinsk bioteknologi -- Medicinsk bioteknologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Medical Biotechnology -- Medical Biotechnology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Farmaceutiska vetenskaper (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Pharmaceutical Sciences (hsv//eng)
Keyword
- Blood brain barrier
- Drug development
- iPSC
- Microphysiological systems
- Organs-on-chips
- Pharmaceutical
- Stem cells
- Tissue chips
- Blood
- Drug products
- Neurodegenerative diseases
- Blood-brain barrier
- Induced pluripotent stem cells
- On chips
- Pharmaceutical company
- Pharmaceutical industry
- Physiological response
- Physiological models
- Bioinformatik
- Bioinformatics
- INF502 Biomarkers
- INF502 Biomarkörer
- Microphysiological systems
- Organs-on-chips
- Tissue chips
- Stem cells
- iPSC
- Blood brain barrier
- Pharmaceutical
- Drug development
- in-vitro model
- drug discovery
- efficient generation
- endothelial-cells
- cns
- differentiation
- inflammation
- permeability
- penetration
- crispr/cas9
- Pharmacology & Pharmacy
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database